摘要
目的:探讨普米克令舒结合孟鲁司特在小儿支气管哮喘中的应用及有效率分析。方法:选取2019年1月—2020年11月在我院确诊的162例小儿支气管哮喘患儿,采用随机数表法将支气管哮喘患儿分为对照组(n=81)和观察组(n=81)。对照组支气管哮喘患儿采用普米克令舒治疗,观察组采用普米克令舒结合孟鲁司特治疗,均持续治疗15天。观察并比较两组患儿临床疗效、肺功能指标以及细胞免疫指标并记录治疗期间不良反应发生率情况。结果:所纳入观察组支气管患者治疗的有效率为93.83%,明显高于对照组的83.95%(x 2=4.702,P=0.030)。治疗后两组第1秒所能呼出的最大气体量与肺功能仪器对患者计算出预计值的比值(FEV1%pred)、肺活量(FVC)、第1秒所能呼出的最大气体量占用力肺活量百分比(FEV1/FVC)指标均显著下降,且观察组FEV1%pred、FVC、FEV1/FVC指标均较对照组支气管哮喘患者改善明显(P<0.05);治疗后两组CD4+和CD4+/CD8+指标均显著下降,CD8+水平均显著升高,且观察组CD4+和CD4+/CD8+指标均低于对照组,CD8+水平均高于对照组(P<0.05);两组总不良反应发生率无明显差异(x 2=0.066,P=0.798)。结论:普米克令舒结合孟鲁司特治疗小儿支气管哮喘患者疗效确切,患儿肺功能指标和免疫功能指标得到有效好转,不良反应较少。
Objective:To investigate the application and efficacy analysis of pulmicorin combined with montelukast in children with bronchial asthma.Methods:A total of 162 children with bronchial asthma diagnosed in our hospital from January 2019 to November 2020 were selected,and the children with bronchial asthma were divided into the control group(n=81)and the observation group(n=81)by random number table method.The children with bronchial asthma in the control group were treated with pulmicoride,and the observation group was treated with pulmicorin combined with montelukast,and the treatment was continued for 15 days.The clinical efficacy,pulmonary function indexes and cellular immune indexes of the two groups were observed and compared,and the incidence of adverse reactions during treatment was recorded.Results:The effective rate of bronchial patients in the included observation group was 93.83%,which was significantly higher than 83.95%in the control group(x 2=4.702,P=0.030).After treatment,the ratio of the maximum gas volume that can be exhaled in the first second in the two groups to the predicted value calculated by the pulmonary function instrument for the patient(FEV1%pred),vital capacity(FVC),and the maximum volume of gas that can be exhaled in the first second.Force vital capacity The percentage(FEV1/FVC)indexes were significantly decreased,and the indexes of FEV1%pred,FVC,and FEV1/FVC in the observation group were significantly improved compared with those in the control group(P<0.05).Significantly decreased,CD8+levels were significantly increased,and the CD4+and CD4+/CD8+indexes in the observation group were lower than those in the control group,and the CD8+levels were higher than those in the control group(P<0.05);there was no significant difference in the incidence of total adverse reactions between the two groups(x 2=0.066,P=0.798).Conclusion:Pulmicorin combined with montelukast has definite curative effect in the treatment of children with bronchial asthma.The children's pulmonary function indexes and immu
作者
郭莉丽
徐杰
Guo Lili(Department of Pediatrics,Jiangmen Maternal and Child Health Hospital,Jiangmen Guangdong 529000)
出处
《黑龙江医药》
CAS
2022年第5期1104-1107,共4页
Heilongjiang Medicine journal
